What Intrommune Therapeutics does

Intrommune Therapeutics is a New York-based clinical-stage biotechnology company developing Oral Mucosal Immunotherapy (OMIT), a proprietary drug delivery platform that embeds allergenic proteins in a fully functional toothpaste for daily administration during routine toothbrushing. The platform leverages the immunologically active areas of the oral cavity to deliver allergen proteins to Oral Langerhans cells, which process and present allergen identifiers to the immune system to trigger tolerance. The company's lead product candidate, INT301, is a peanut protein toothpaste designed for peanut allergy desensitization; it completed a Phase 1 OMEGA clinical trial in 32 adult patients, demonstrating 97% adherence, 100% highest-dose tolerance, and no moderate or severe systemic reactions. A second pipeline product, INT302 (Multifood), is in development to extend the OMIT platform to multiple food allergens.

The company targets individuals diagnosed with food allergies—approximately 33 million Americans, including nearly 6 million children, with peanut allergy affecting roughly 2% of the population—as well as the board-certified allergists and immunologists who would prescribe treatment. Upon FDA approval, Intrommune would generate revenue through prescription pharmaceutical sales via specialty pharmacy and allergist office distribution channels. The business model is pre-revenue: the company has no commercial products and no disclosed pricing, relying on capital markets and partnership funding to advance clinical development.

Intrommune has raised approximately $6.3M in disclosed funding across seed and early-stage rounds (most recent: $6M in June 2021 from Chemical Angel Network, Red Bear Angels, Robin Hood Ventures, and Timberline Investments). FDA IND clearance has been granted for INT301, and Phase 2 pediatric trials are planned. The company operates with 1-10 employees and is led by CEO Michael Nelson, with a board strengthened in March 2024 by the addition of Executive Chairman Hem Pandya and director Dr. Jonathan Rich. A strategic collaboration with Inimmune Corporation was announced in January 2024 to co-develop next-generation OMIT therapies. The allergy immunotherapy market is projected to reach $5.64 billion by 2030.

Name

Intrommune Therapeutics

Legal name

Intrommune Therapeutics, Inc.

Website

https://intrommune.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Intrommune Therapeutics is a clinical-stage biotechnology company developing Oral Mucosal Immunotherapy (OMIT), a proprietary toothpaste-based drug delivery platform for food allergy desensitization. Its lead product INT301 (peanut protein toothpaste) has completed Phase 1 trials.

Ownership category

akta.pro rank

Product category

Allergy Immunotherapy Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

akta.pro secondary industry

Prefilled Syringes & Safety Syringes (HLAHAIAA)

Keywords

• Oral mucosal immunotherapy
• Food allergy treatment
• Peanut allergy therapy
• Allergen desensitization
• Clinical-stage biotechnology

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Prescription Product: Intrommune is developing INT301 and INT302 as prescription pharmaceutical products for food allergy treatment. Upon FDA approval, the company would generate revenue through prescription sales of its therapeutic toothpaste products for peanut and other food allergies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Intrommune Therapeutics is a clinical-stage biotechnology company that develops prescription pharmaceutical products using its proprietary Oral Mucosal Immunotherapy (OMIT) platform, which embeds allergenic proteins in fully functional toothpaste for the daily treatment of food allergies. Its lead product candidate INT301 is a peanut protein toothpaste for peanut allergy desensitization, with INT302 (Multifood) in development for multiple food allergies.

Product overview

Intrommune Therapeutics has developed a unified platform-plus-products architecture centered on its Oral Mucosal Immunotherapy (OMIT) technology. The OMIT platform serves as the core technology, delivering allergenic proteins via a specially formulated toothpaste for daily desensitization. The company operates two lead products built on this platform: INT301 (peanut protein toothpaste) for peanut allergy treatment, which has completed Phase 1 clinical trials; and INT302 (Multifood) for multi-food allergy treatment, currently in development. Both products utilize the same OMIT toothpaste delivery mechanism, with the platform providing the foundational stabilization and delivery technology while each product targets specific food allergens.

Differentiator

Problem solved

Functional benefit

Brands

• OMIT (Oral Mucosal Immunotherapy): Proprietary drug delivery platform that embeds allergenic proteins in a fully functional toothpaste for food allergy treatment.
• INT301
• INT302 (Multifood)

Products and services

• INT301 (Peanut Protein Toothpaste) INT301 is Intrommune's lead product candidate - a specially formulated toothpaste containing peanut protein for oral mucosal immunotherapy (OMIT) to treat peanut allergy. Delivers allergenic proteins via daily toothbrushing for gradual desensitization to peanut allergen, intended for individuals diagnosed with peanut allergy and prescribed by allergists.
• INT302 (Multifood) INT302 (Multifood) is Intrommune's next-generation product candidate designed to help individuals suffering with multiple food allergies. Built on the OMIT platform, it is intended to significantly raise a patient's immune threshold through daily OMIT toothpaste use, providing protection against accidental exposure to multiple food allergens beyond peanut.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Inimmune CorporationcoreStrategic or Co-development Partner · 8 January 2024In January 2024, Intrommune and Inimmune announced a strategic collaboration to develop a next-generation oral mucosal immunotherapy combining Intrommune's disease-modifying OMIT treatment with Inimmune's proprietary rapid desensitization technology. The combination aims to provide rapid and long-term relief from peanut allergy symptoms. Both companies are clinical-stage, with Intrommune's INT301 having completed Phase 1 trials and Inimmune advancing its own immunotherapy platform.
• Bio NJminorOthersPartner organization supporting biotechnology companies in New Jersey, appearing in the Partners section of Intrommune's website.
• Circuit ClinicalminorChannel Partner/ Reseller/ DistributorCircuit Clinical is a dedicated research organization that connects patients with clinical trials. Intrommune struck a deal with Circuit Clinical to support clinical trial patient recruitment and engagement.
• Food Allergy & Anaphylaxis Connection Team (FAACT)minorOthersPatient advocacy organization representing individuals with food allergies. Listed as a partner in Intrommune's ecosystem.
• JFK CommunicationsminorOthersHealthcare communications and public relations partner supporting Intrommune's media relations and communications strategy.
• The Solution LabminorOthersPartner organization listed in Intrommune's ecosystem of supporting organizations.
• We Heal FoundationminorOthersNon-profit foundation supporting healthcare initiatives, listed as a partner organization.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Aimmune Therapeutics (Nestlé Health Science): Aimmune developed Palforzia, the first FDA-approved oral immunotherapy for peanut allergy, and was acquired by Nestlé Health Science in 2020. It is the most direct competitive comparable to Intrommune's INT301, addressing the same patient population with the same modality class (oral immunotherapy).
• DBV Technologies: DBV is developing Viaskin, an epicutaneous immunotherapy patch for peanut and other food allergies. It competes with Intrommune in the same food allergy immunotherapy category but uses a different delivery modality (skin patch vs. oral mucosa toothpaste), targeting the same allergist prescriber base.

Emerging players

• Alladapt Immunotherapeutics: Alladapt is developing a multifood oral immunotherapy for treating allergies to one or multiple foods simultaneously, parallel to Intrommune's INT302 multifood program. Both companies are clinical-stage and target the multifood allergy patient segment.
• COUR Pharmaceuticals (formerly Camallergy): COUR is developing immune-modifying nanoparticle therapies for food allergies including peanut. It overlaps with Intrommune in peanut allergy treatment but uses a distinct nanoparticle delivery technology rather than oral mucosal immunotherapy.
• Vedanta Biosciences: Vedanta is developing microbiome-based immunotherapies for food allergy, including a defined bacterial consortium approach. While the modality is distinct from Intrommune's OMIT, both companies target disease-modifying treatment of food allergies and compete for similar investor capital and strategic attention.
• Prota Therapeutics: Prota was an Australian biotech developing a multifood allergy immunotherapy using a novel delivery format. While it has undergone strategic restructuring, its prior program is comparable to Intrommune's INT302 multifood candidate as both target multiple food allergens with a single therapy.

Broad incumbents

• Allergy Therapeutics: Allergy Therapeutics is an established specialty immunology company developing allergy vaccines and immunotherapies across multiple allergens. While it is not focused specifically on food allergy, it is a broad incumbent in the allergy immunotherapy space relevant to Intrommune's commercial pathway.
• ALK-Abelló: ALK-Abelló is a global leader in allergy immunotherapy, with a broad portfolio of subcutaneous and sublingual immunotherapy products. As a large established allergy immunotherapy company, it represents a relevant comparable for Intrommune's eventual commercial strategy and scale-up.
• Stallergenes Greer: Stallergenes Greer is a global allergy immunotherapy company offering sublingual and subcutaneous treatments for respiratory and food allergies. It serves as a broad incumbent comparable in the allergy immunotherapy category that Intrommune is entering.

Others

• Inimmune Corporation: Inimmune is a clinical-stage immunotherapy company and Intrommune's January 2024 strategic co-development partner. The collaboration combines Intrommune's OMIT delivery platform with Inimmune's proprietary rapid desensitization technology, making it the most directly operationally integrated peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/intrommune
• Facebookfacebook.com/intrommune
• LinkedInlinkedin.com/company/intrommune-therapeutics
• Instagraminstagram.com/intrommune

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intrommune Therapeutics